← All trials
NCT05658146
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 5, 2023
- Primary completion
- Jul 24, 2023
- Completion date
- Jul 24, 2023
- First posted
- Dec 20, 2022
- Last posted
- Dec 20, 2022
- Enrollment
- 96
- Arms / groups
- 6 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Bristol-Myers SquibbLead sponsor
- Bristol-Myers SquibbOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.